Preclinical Assays in Cancer Therapy

Personalized cancer therapy requires detailed insight into the mechanisms underlying the response of individual tumors to (combinations of) targeted therapeutics and chemotherapy drugs. Understanding mechanisms of acquired therapy resistance is equally important since most patients with disseminated cancer eventually die due of tumors that are refractory to all available treatments.
This symposium will provide an overview of preclinical approaches aimed at understanding basic mechanisms of therapy response and resistance in order to improve personalized cancer therapy. The emphasis of this course will be on the use of genetically engineered mouse models and patient-derived xenograft (PDX) models for in vivo preclinical research, but also in vitro preclinical assays employing established tumor cell lines and functional genomics approaches will be discussed. During the 3-day symposium national and international experts will present current approaches used in the field.


+ show speakers and program
Wednesday, September 26, 2012
Session 1: Technology
09.00 – 09.40 Organ Structures Hans Clevers - Hubrecht Institute – Utrecht
09.40 – 10.20 Cell Line derived xenograft models Patricia Vrignaud – Sanofi Aventis
10.20 – 10.50 Coffee break Foyer
10.50 – 11.30 Human Xenograft in mice: technical aspects Marie-France Poupon - Institute Curie -Paris
11.30 – 12.10 Fast-track production of GEM models of human cancer Ivo Huijbers – NKI-AVL – Amsterdam
12.10 – 12.50 Preclinical Imaging Peter Friedl – NCMLS – Nijmegen
12.50 – 14.00 Lunch - posters in bar Foyer
Session 2: GEMMs
14.00 – 14.40 GEM models of intestinal cancer Owen Sansom – Beatson Institute – Glasgow
14.40 – 15.20 GEM models of pancreas and non small cell lung cancer Mariano Barbacid – CNIO– Madrid
15.20 – 15.50 Coffee/tea break Bar Tiffany’s
15.50 – 16.30 GEM models of small cell lung cancer and mesothelioma Anton Berns – NKI-AVL – Amsterdam
16.30 – 17.10 GEM models of breast cancer Jos Jonkers – NKI-AVL – Amsterdam
17.10 – 17.50 Humanized GEM models Alfred Schinkel – NKI-AVL –Amsterdam
17.50 – 19.00 posters and drinks Bar

Thursday, September 27, 2012
Session 3: PDX models
09.00 – 09.40 PDX models of colorectal cancer Virginie Dangles-Marie – Institute Curie Paris
09.40 – 10.20 Targeted therapies in PDX models of colorectal cancer Alberto Bardelli – University of Torino
10.20 – 10.50 Coffee/tea break Foyer
10.50 – 11.30 PDX models of pancreatic cancer Manuel Hidalgo – CNIO – Madrid
11.30 - 12.10 PDX models of breast cancer Elisabetta Marangoni – Institute Curie Paris
12.10 - 12.50 Histopathology of xenograft models Jean-Jacques Fontaine – ENVA – Paris
12.50 – 14.00 Lunch - posters in bar Foyer
Session 4: Applications
14.00 – 14.40 Angiogenesis Kari Alitalo – University of Helsinki
14.40 – 15.20 Metastasis in xenograft models Suzanne Eccles - ICR- London
15.20 – 15.50 Coffee/tea break Foyer
15.50 – 16.30 Ethics Suzanne Eccles – ICR - London
16.30 – 17.10 Chemoresistance in GEMMs Sven Rottenberg - NKI-AVL Amsterdam
17.10 - 17.50 Use of humanized mouse models for drug development Holger Kissel– Taconic Artemis
17.50 – 19.00 posters and drinks Bar
19.00 - ? Social event Amsterdam

Friday, September 28, 2012
Session 5: Applications
09.00 – 09.40 Impact of the immune system on chemotherapy response Karin de Visser - NKI-AVL – Amsterdam
09.40 – 10.20 Antibodies to target cancer Frank Herting – Roche
10.20 – 10.50 Coffee/tea break Foyer
11.00 – 12.00 Keynote lecture: protection of telomeres Titia de Lange – Rockefeller Institute - New York
12.10 - 12.50 Mouse Clinic Ken Olive – Colombia University - New York
12.50 – 14.00 Lunch Foyer
14.00 End of program


26 Sep - 28 Sep 2012
Amsterdam
Netherlands
meeting website